ClinicalTrials.govpublic full text
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
ptsd, alzheimer disease, brain diseases, neuro-degenerative disease, major depressive disorder, treatment resistant depression, nmda, alzheimer's disease, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 916380
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.